U07.1
Conditions
Interventions
Group 1: Patients with PCR-secured Sars-Cov2 infection and inpatient treatment are included.
During the initial inpatient stay, data of examinations indicated in clinical routine is collected, which c
Sponsors
Universitätsherzzentrum Freiburg Bad Krozingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - PCR-secured SARS-CoV-2 infection - Clinically manifest signs of SARS-CoV-2 infection - Ability / willingness to come to the 6-month follow-up
Exclusion criteria
Exclusion criteria: - Missing written informed consent - Contraindication for MRI examination according to the current guidelines (e.g. metal implants, severe allergy to MRI contrast media) - severe renal failure (creatinine clearance <30ml / min / 1.73m2) - People who are in a dependency or employment relationship with the clinic or examiner stand - Placement in an institution based on a judicial or official order - Demential development or other illness (e.g. substance abuse) that a Understanding of the clarification in the study and / or a legally effective clarification makes unlikely. - pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left and right ventricular ejection fraction (echo and MRI) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| • Markers for myocardial damage that are not detected by a decrease in the ejection fraction (including blood: highly sensitive troponin T, NT-proBNP / ECG: QRS fragmentation / echo: myocardial strain, pulmonary arterial pressure / MRI: late enhancement ) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months • Cardiovascular event rate within 12 months (death, myocardial infarction, hospitalization for heart failure) | — |
Countries
Germany
Contacts
Public ContactNikolaus Löffelhardt
Universitätsherzzentrum Freiburg Bad Krozingen
Outcome results
None listed